City Hill Ventures

City Hill Ventures, LLC is a venture capital firm established in 2010 and based in San Diego, California, a prominent hub for life sciences. The firm specializes in making seed and early-stage investments in private companies, focusing primarily on the life sciences sector, which includes therapeutics, diagnostics, and medical devices. Additionally, City Hill Ventures is interested in health care technology and other related fields, aiming to support innovative solutions that enhance health care and medical advancements.

Zachary Hornby

Operating Principal

17 past transactions

Maze Therapeutics

Venture Round in 2022
Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific patient populations.

Viron

Series B in 2021
Viron is a biopharmaceutical company that uses breakthrough discovery and novel technologies to identify and develop patent-pending high-value therapies for currently unarguable porosome protein and lipid targets in cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Breakthroughs in genomics and gene editing technologies, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and image analysis using AI machine learning and high-throughput screening have transformed the drug discovery landscape.

Viron

Series B in 2021
Viron is a biopharmaceutical company that uses breakthrough discovery and novel technologies to identify and develop patent-pending high-value therapies for currently unarguable porosome protein and lipid targets in cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Breakthroughs in genomics and gene editing technologies, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and image analysis using AI machine learning and high-throughput screening have transformed the drug discovery landscape.

Erasca

Series B in 2020
Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer. Erasca was founded in 2018 and is headquartered in San Diego, California.

Maze Therapeutics

Venture Round in 2019
Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific patient populations.

Boundless Bio

Series A in 2019
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.

Viron

Series A in 2019
Viron is a biopharmaceutical company that uses breakthrough discovery and novel technologies to identify and develop patent-pending high-value therapies for currently unarguable porosome protein and lipid targets in cancer, Alzheimer's, diabetes, neurological, digestive, and immune disorders. Breakthroughs in genomics and gene editing technologies, stem cell biology, patient-derived organoids, cryo-electron microscopy, synthetic biology, small molecule screening, and image analysis using AI machine learning and high-throughput screening have transformed the drug discovery landscape.

Erasca

Series A in 2018
Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer. Erasca was founded in 2018 and is headquartered in San Diego, California.

Bonti

Series C in 2018
Endurance Biotech is a biotechnology company based in Orange, California. The company was founded in 2015 by Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad.

Bonti

Series B in 2017
Endurance Biotech is a biotechnology company based in Orange, California. The company was founded in 2015 by Fauad Hasan, Mike Jarpe, Susan Abushakra, and Wajdie Ahmad.

Flex Pharma

Venture Round in 2014
Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps, cramps and spasms associated.

Independa

Series B in 2014
Independa subscription services address today's gap in integrated solutions to deliver cost effective Technology-enabled Independent Living. We help family caregivers help their loved ones live home longer, safer and more comfortably. Independa will revolutionize how family caregivers support and care for their senior loved ones, providing a cost effective and real time answer to the key question of "How's my loved one doing?"

Independa

Series A in 2013
Independa subscription services address today's gap in integrated solutions to deliver cost effective Technology-enabled Independent Living. We help family caregivers help their loved ones live home longer, safer and more comfortably. Independa will revolutionize how family caregivers support and care for their senior loved ones, providing a cost effective and real time answer to the key question of "How's my loved one doing?"

Ignyta

Series B in 2012
Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide. Ignyta was incorporated in 2011 and operates in San Diego, California.

Independa

Venture Round in 2012
Independa subscription services address today's gap in integrated solutions to deliver cost effective Technology-enabled Independent Living. We help family caregivers help their loved ones live home longer, safer and more comfortably. Independa will revolutionize how family caregivers support and care for their senior loved ones, providing a cost effective and real time answer to the key question of "How's my loved one doing?"

Eclipse Therapeutics

Seed Round in 2011
Eclipse Therapeutics, Inc. ("Eclipse") is a private biotechnology company dedicated to the discovery and development of therapeutics that target cancer stem cells (CSCs) and other forms of innovative cancer treatment.

Independa

Venture Round in 2011
Independa subscription services address today's gap in integrated solutions to deliver cost effective Technology-enabled Independent Living. We help family caregivers help their loved ones live home longer, safer and more comfortably. Independa will revolutionize how family caregivers support and care for their senior loved ones, providing a cost effective and real time answer to the key question of "How's my loved one doing?"
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.